GleamWall
中文EN

PLRX PLIANT THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1746473 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY48.5%
TTM EPS YoY49.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-55.3%
ROA-40.5%
ROIC (approx.)-63.7%
Asset turnover—

Leverage & solvency

Liabilities / assets25.5%
Debt / equity0.00x
Current ratio8.05x
Interest coverage-698.18x

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———————$0
R&D expense$17.93M$16.73M$13.58M$15.59M$17.94M$32.20M$43.44M$38.79M
SG&A expense$7.81M$7.13M$8.19M$7.99M$10.33M$13.39M$15.50M$14.53M
Operating income-$25.74M-$23.86M-$21.77M-$23.58M-$28.27M-$45.59M-$58.94M-$53.32M
Interest expense$0$0$0$136,000$815,000$809,000$799,000$834,000
Income tax$0$0$0$0$0$0$0$0
Net income-$24.38M-$22.37M-$20.04M-$23.58M-$26.30M-$43.30M-$56.17M-$49.73M
EBITDA-$25.54M-$23.66M-$21.51M-$23.21M-$27.87M-$45.19M-$58.49M-$52.86M
EPS (basic)-0.39-0.36-0.32—-0.43-0.71-0.92—
EPS (diluted)-0.39-0.36-0.32—-0.43-0.71-0.92—
Dividends declared per share0.000.000.000.000.000.000.000.00
Weighted avg. shares (diluted)61.94M61.92M61.80M—61.41M61.39M61.22M—
Balance sheet
Cash & equivalents$26.57M$24.88M$22.19M$45.45M$95.21M$88.30M$93.42M$72.67M
Short-term investments$114.52M$133.22M$148.70M$145.50M$148.06M$176.05M$213.71M$284.54M
Current assets$144.21M$163.14M$174.93M$196.45M$245.59M$267.44M$311.19M$362.26M
PP&E, net$2.18M$2.41M$2.66M$2.94M$4.34M$4.89M$5.24M$5.53M
Total assets$169.88M$189.88M$202.60M$225.23M$276.60M$299.82M$344.77M$396.95M
Current liabilities$17.92M$16.48M$10.36M$16.36M$17.62M$20.59M$28.20M$33.22M
Long-term debt$0$0$0$0$30.44M$30.36M$30.28M$30.21M
Total debt$0$0$0$0$30.44M$30.36M$30.28M$30.21M
Total liabilities$43.24M$42.95M$37.43M$44.02M$76.29M$79.74M$87.61M$92.87M
Shareholders' equity$126.63M$146.93M$165.17M$181.21M$200.31M$220.08M$257.16M$304.08M
Net debt-$26.57M-$24.88M-$22.19M-$45.45M-$64.78M-$57.94M-$63.13M-$42.46M
Shares outstanding61.99M61.92M61.91M61.45M61.45M61.39M61.39M60.86M
Cash flow statement
Operating cash flow-$16.98M-$12.80M-$19.23M-$17.79M-$21.08M-$40.60M-$48.86M-$47.66M
Capital expenditure$0$0$0$0$0$112,000$262,000$209,000
Free cash flow-$16.98M-$12.80M-$19.23M-$17.79M-$21.08M-$40.72M-$49.13M-$47.87M
Investing cash flow$18.60M$15.49M-$4.10M$1.77M$27.92M$35.49M$69.11M$39.13M
Financing cash flow$64,000$0$74,000-$32.27M$72,000$0$498,000$102,000
Depreciation & amortization$200,000$200,000$264,000$365,000$400,000$400,000$448,000$458,000
Stock-based compensation$4.15M$4.19M$4.25M$4.53M$6.42M$6.38M$8.91M$8.42M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.